A genetic marker already used to flag risk of a life-threatening reaction to the antibiotic vancomycin also identifies patients at risk of that reaction to lamotrigine – and it is missing from the gene panels clinicians order before prescribing the drug, Vanderbilt Health-led researchers report Sept. 2 in JAMA Network Open.